Scientists test Triple-Threat drug cocktail for Tough-to-Treat blood cancer
NCT ID NCT02446236
Summary
This early-stage study aims to find the safest and most effective dose of a three-drug combination (ibrutinib, lenalidomide, and rituximab) for adults with mantle cell lymphoma that has returned or stopped responding to prior treatment. The main goal is to see how much of the new drug ibrutinib can be safely added to the other two drugs. Researchers will also check if the combination helps control the cancer and monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.